Lineage Cell Therapeutics Inc (LCTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lineage Cell Therapeutics Inc (LCTX) has a cash flow conversion efficiency ratio of -0.174x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.62 Million) by net assets ($20.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Lineage Cell Therapeutics Inc to measure how much of total assets are equity-financed.
Lineage Cell Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1991–2024)
This chart illustrates how Lineage Cell Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Lineage Cell Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Lineage Cell Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lineage Cell Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sky Harbour Group Corp
NYSE MKT:SKYH
|
-0.012x |
|
Nanjing Res In of Surveying Mapping
SHE:300826
|
0.002x |
|
Meteoric Resources NL
AU:MEI
|
-2.091x |
|
IMC S.A.
F:IM4
|
0.194x |
|
Integrated Diagnostics Holdings PLC
LSE:IDHC
|
0.051x |
|
Shanxi C&Y Pharmaceutical Group Co Ltd
SHE:300254
|
0.103x |
|
Chaun-Choung Technology Corp
TW:6230
|
0.023x |
|
Ernst Russ AG
XETRA:ERAG
|
0.067x |
Annual Cash Flow Conversion Efficiency for Lineage Cell Therapeutics Inc (1991–2024)
The table below shows the annual cash flow conversion efficiency of Lineage Cell Therapeutics Inc from 1991 to 2024. For the full company profile with market capitalisation and key ratios, see Lineage Cell Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $77.01 Million | $-23.09 Million | -0.300x | +34.90% |
| 2023-12-31 | $62.02 Million | $-28.57 Million | -0.461x | -3228.58% |
| 2022-12-31 | $71.94 Million | $1.06 Million | 0.015x | +105.68% |
| 2021-12-31 | $90.90 Million | $-23.56 Million | -0.259x | -24.83% |
| 2020-12-31 | $95.13 Million | $-19.75 Million | -0.208x | +27.69% |
| 2019-12-31 | $111.25 Million | $-31.95 Million | -0.287x | +14.22% |
| 2018-12-31 | $92.25 Million | $-30.88 Million | -0.335x | -80.20% |
| 2017-12-31 | $164.26 Million | $-30.52 Million | -0.186x | +42.72% |
| 2016-12-31 | $130.51 Million | $-42.33 Million | -0.324x | +44.34% |
| 2015-12-31 | $76.45 Million | $-44.54 Million | -0.583x | +5.94% |
| 2014-12-31 | $62.72 Million | $-38.85 Million | -0.619x | +11.28% |
| 2013-12-31 | $42.26 Million | $-29.51 Million | -0.698x | +13.80% |
| 2012-12-31 | $24.29 Million | $-19.68 Million | -0.810x | -147.04% |
| 2011-12-31 | $41.46 Million | $-13.59 Million | -0.328x | -109.58% |
| 2010-12-31 | $49.43 Million | $-7.73 Million | -0.156x | +59.43% |
| 2009-12-31 | $11.05 Million | $-4.26 Million | -0.386x | -204.49% |
| 2008-12-31 | $-4.35 Million | $-1.60 Million | 0.369x | -9.33% |
| 2007-12-31 | $-3.05 Million | $-1.24 Million | 0.407x | -39.85% |
| 2006-12-31 | $-1.87 Million | $-1.26 Million | 0.677x | -90.59% |
| 2005-12-31 | $-196.58K | $-1.41 Million | 7.194x | +261.40% |
| 2004-12-31 | $344.77K | $-1.54 Million | -4.457x | -1756.11% |
| 2003-12-31 | $-2.43 Million | $-654.14K | 0.269x | -85.20% |
| 2002-12-31 | $-1.17 Million | $-2.13 Million | 1.818x | -94.39% |
| 2001-12-31 | $-99.09K | $-3.21 Million | 32.392x | +978.80% |
| 2000-12-31 | $1.32 Million | $-4.86 Million | -3.686x | -326.31% |
| 1999-12-31 | $5.08 Million | $-4.39 Million | -0.865x | +1.19% |
| 1998-12-31 | $2.40 Million | $-2.10 Million | -0.875x | -337.50% |
| 1997-12-31 | $6.50 Million | $-1.30 Million | -0.200x | +73.33% |
| 1996-12-31 | $2.80 Million | $-2.10 Million | -0.750x | 0.00% |
| 1995-12-31 | $2.80 Million | $-2.10 Million | -0.750x | -20.00% |
| 1994-12-31 | $3.20 Million | $-2.00 Million | -0.625x | -126.56% |
| 1993-12-31 | $5.80 Million | $-1.60 Million | -0.276x | +27.85% |
| 1992-12-31 | $3.40 Million | $-1.30 Million | -0.382x | -193.14% |
| 1991-12-31 | $4.60 Million | $-600.00K | -0.130x | -- |
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more